(FOREMOST) Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis


This study aims to explore the efficacy of the drug Apremilast in treating early stages of Psoriatic arthritis (PsA) with limited joint involvement. Apremilast currently is used as an effective treatment for PsA at later stages of disease activity.

This study will determine whether the drug is also effective at preventing joint involvement and further progression of the disease.

Patients who have a recent diagnosis of PsA (2 years or less) that are interested in participating in the study are encouraged to contact the study team to see if they qualify.


  • 18 years and older
  • Disease duration since diagnosis ≥ 3 months and ≤ 24 months as based on the Classification Criteria for Psoriatic Arthritis (CASPAR)
  • SJC AND TJC must be >1 and ≤ 4
  • Stable doses of protocol-allowed PsA medications
  • General good health (except for psoriatic arthritis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (Note: The definition of good health means a subject does not have uncontrolled significant comorbid conditions).
  • Comply with protocol-required contraception measures

Additional inclusion and exclusion criteria apply. 


18 to 65
65 and over




Psoriatic arthritis

Principal Investigator

Michael R Bubb, M.D.



Contact Information



Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams